Cumulative Effects of Strontium Ranelate and Impact Exercise on Bone Mass in Ovariectomized Rats.
Animals
Apoptosis
/ drug effects
Biomarkers
/ metabolism
Biomechanical Phenomena
/ drug effects
Body Composition
/ drug effects
Bone Density
/ drug effects
Bone Remodeling
/ drug effects
Cancellous Bone
/ drug effects
Cortical Bone
/ drug effects
Female
Femur
/ drug effects
Lipids
/ chemistry
Osteocytes
/ drug effects
Ovariectomy
Physical Conditioning, Animal
Rats, Wistar
Thiophenes
/ pharmacology
bone status
impact exercise
ovariectomized rats
strontium ranelate
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
28
02
2021
revised:
11
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
23
4
2021
Statut:
epublish
Résumé
To explore the effect of physical exercise (EXE), strontium ranelate (SR), or their combination on bone status in ovariectomized (OVX) rats. Sixty female Wistar rats were randomized to one of five groups: sham (Sh), OVX (O), OVX+EXE (OE), OVX+SR (OSR), and OVX+EXE+SR (OESR). Animals in EXE groups were subjected to 10 drops per day (45 cm in height); rats in SR groups received 625 mg/kg/day of SR, 5 days/week for 8 weeks. Bone mineral density (BMD) and bone mineral content (BMC, dual-energy X-ray absorptiometry (DXA)), mechanical strength of the left femur (three-point bending test), and femur microarchitecture of (micro-computed tomography imaging, microCT) analyses were performed to characterize biomechanical and trabecular/cortical structure. Bone remodeling, osteocyte apoptosis, and lipid content were evaluated by ELISA and immunofluorescence tests. In OVX rats, whole-body BMD, trabecular parameters, and osteocalcin (OCN) levels decreased, while weight, lean/fat mass, osteocyte apoptosis, and lipid content all increased. EXE after ovariectomy improved BMD and BMC, trabecular parameters, cross-sectional area (CSA), moment of inertia, and OCN levels while decreasing osteocyte apoptosis and lipid content. SR treatment increased BMD and BMC, trabecular parameters, CSA, stiffness, OCN, and alkaline phosphatase (ALP) levels. Furthermore, fat mass, N-telopeptide (NTX) level, osteocyte apoptosis, and lipid content significantly decreased. The combination of both EXE and SR improved bone parameters compared with EXE or SR alone. EXE and SR had positive and synergistic effects on bone formation and resorption.
Identifiants
pubmed: 33809778
pii: ijms22063040
doi: 10.3390/ijms22063040
pmc: PMC8002366
pii:
doi:
Substances chimiques
Biomarkers
0
Lipids
0
Thiophenes
0
strontium ranelate
04NQ160FRU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 2010 Aug 13;285(33):25251-8
pubmed: 20554534
Int J Sports Med. 1995 Aug;16(6):364-7
pubmed: 7591386
J Mech Behav Biomed Mater. 2014 Jan;29:161-70
pubmed: 24090875
J Biol Chem. 2006 Aug 18;281(33):23698-711
pubmed: 16790443
Bone. 2008 Jan;42(1):129-38
pubmed: 17945546
Comput Methods Programs Biomed. 2016 Sep;133:133-141
pubmed: 27393805
J Histochem Cytochem. 1985 Aug;33(8):833-6
pubmed: 4020099
J Bone Miner Metab. 2007;25(6):345-53
pubmed: 17968486
J Bone Miner Res. 2010 Jul;25(7):1468-86
pubmed: 20533309
J Bone Miner Res. 2008 Jun;23(6):879-86
pubmed: 18282131
Calcif Tissue Int. 1993 Mar;52(3):234-8
pubmed: 8481838
Calcif Tissue Int. 1993 Oct;53(4):269-77
pubmed: 8275356
J Bone Miner Res. 2004 Dec;19(12):2012-20
pubmed: 15537445
J Biol Chem. 2005 Dec 30;280(52):42952-9
pubmed: 16269410
Osteoporos Int. 2009 Apr;20(4):653-64
pubmed: 18763010
Aust Prescr. 2016 Apr;39(2):40-6
pubmed: 27340321
Pathol Biol (Paris). 2005 Dec;53(10):576-80
pubmed: 16364809
Biomed Res Int. 2018 Dec 23;2018:4840531
pubmed: 30671455
Bone. 2011 Sep;49(3):543-52
pubmed: 21689804
Acta Endocrinol (Buchar). 2018 Jan-Mar;14(1):90-101
pubmed: 31149241
Physiol Behav. 1987;39(3):361-5
pubmed: 3575476
J Bone Miner Res. 2001 Feb;16(2):195-201
pubmed: 11204418
Med Eng Phys. 2008 Nov;30(9):1112-8
pubmed: 18595763
Bone. 2012 Jan;50(1):209-17
pubmed: 22075208
J Biol Chem. 2005 May 20;280(20):19883-7
pubmed: 15778503
Biochem Biophys Res Commun. 2000 Feb 16;268(2):414-9
pubmed: 10679219
Bone. 2008 Apr;42(4):606-15
pubmed: 18280232
Clin Exp Rheumatol. 2006 Mar-Apr;24(2):191-5
pubmed: 16762158
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1019-24
pubmed: 18187040
Eur J Appl Physiol. 2011 Dec;111(12):2931-40
pubmed: 21437605
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):514-22
pubmed: 25166042
Bone. 2008 Apr;42(4):660-8
pubmed: 18291744
Biochem Pharmacol. 2007 Aug 1;74(3):438-47
pubmed: 17531955
Calcif Tissue Int. 2016 Oct;99(4):408-22
pubmed: 27272029
J Appl Physiol (1985). 2003 Sep;95(3):1032-7
pubmed: 12754179
Eur Cell Mater. 2012 Sep 24;24:278-91
pubmed: 23007912